Diagnostics

New data shows firms with active board oversight of AI see huge ROI, yet most boards are disengaged. This governance gap is now a top business risk.

DNA Script's global expansion brings benchtop DNA printers to new markets, promising to accelerate research and decentralize biotech supply chains.

A new network for consumer ads is launching in 30,000 clinics, offering brands a trusted space but raising new questions about ethics and data privacy.

A new strategic partnership aims to unite California's life science hubs, creating a streamlined path to capital for medtech and biotech startups.

Activist investor Altai Capital launches a proxy fight at OraSure, alleging chronic underperformance and demanding board seats to force a strategic review.

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

A new injectable dye entering Phase 3 trials promises to make lung cancer cells glow, helping surgeons remove tumors more completely and prevent recurrence.

A simple blood test is revolutionizing Alzheimer's diagnosis. ALZpath's pTau217 antibody is now the industry benchmark, promising earlier detection for millions.

A new collaboration aims to predict immunotherapy success by mapping protein interactions, offering hope for personalized non-small cell lung cancer treatment.

Princess Padmaja Kumari Parmar receives the Mary Tyler Moore Award for her advocacy, bridging a legacy of hope with a modern fight for global T1D equity.

A new exoskeleton, validated by scientific studies, shows a dramatic reduction in muscle strain and discomfort for surgeons, dentists, and industrial workers.

A federal judge has blocked HHS's controversial vaccine schedule and committee appointments, handing a major victory to medical groups fighting for science.

A new alliance aims to overhaul Alzheimer's research, demanding a precision approach for the 65% of patients carrying the high-risk APOE4 gene.

With its lead autoimmune drug nearing FDA review and a new $250M in funding, Zenas BioPharma prepares for a major leap from R&D to market.

Swiss lab-tech firm Tecan posts a major loss after strategic write-downs but launches an ambitious 'Rewired' plan to chase a CHF 1B sales target.

A new analysis of the PREVENT equations clarifies how diabetes and kidney health impact heart risk, enabling earlier, more tailored patient care.

Actelion Pharmaceuticals settles a class action lawsuit for $65M, accused of illegally blocking a cheaper generic for its life-saving hypertension drug.

A new report projects massive growth in cardiovascular devices, driven by AI and minimally invasive tech. But can the healthcare system afford this progress?

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

Aditxt's $36M acquisition of Ignite Proteomics aims to upend cancer therapy by analyzing protein activity, a high-stakes bet for the struggling innovator.